Faecalibacterium prausnitzii, Bacteroides faecis and Roseburia intestinalis attenuate clinical symptoms of experimental colitis by regulating Treg/Th17 cell balance and intestinal barrier integrity

Mohebali, Nooshin; Weigel, Markus; Hain, Torsten; Sütel, Mona; Bull, Jana; Kreikemeyer, Bernd; Breitrück, Anne

doi:10.1016/j.biopha.2023.115568

Cited by 17 publications

(6 citation statements)

References 66 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Besides producing short-chain fatty acids the genus Ruminococcus degrades mucus. Alterations that were consistently found in several other studies in CD patients include a relative reduction of Faecalibacterium prausnitzii and of Roseburia hominis as well [30][31][32][33][34][35][36][37][38][39][40].…”

Section: Microbiota Composition In Patients With Ibdsupporting

confidence: 63%

Microbiota Therapy in Inflammatory Bowel Disease

Biedermann,

Kreienbühl,

Rogler

2024

Visc Med

View full text Add to dashboard Cite

Background: In both Crohn’s disease (CD) and ulcerative colitis (UC), the two major forms of inflammatory bowel disease (IBD) the immune reaction is – at least partially – directed against components of the luminal microbiota of the gut. These immune responses as well as other factors contribute to a phenomenon frequently described as “dysbiosis” meaning an alteration of the composition of the colonic microbiota. To improve the dysbiosis and to restore the normal composition of the colonic microbiota, fecal microbiota transplantation (FMT) has been tested as a therapeutic option to induce and maintain remission in IBD patients. Summary: This review will first discuss changes in the composition of the intestinal microbiota found in IBD patients and second the therapeutic potential of microbiological interventions for the treatment of these patients. FMT has been studied in several clinical trials in both, CD and UC. Reported results and subsequent meta-analyses indicate that FMT may be effective to induce remission in UC. However, the optimal route of FMT, the necessary number of administrations and the question whether life bacteria of freshly prepared stool is more effective than frozen are still unclear. Concepts associated with an optimization of FMT such as the “super donor concept” or the “consortia-approach” will be discussed to illustrate open questions and difficulties associated with microbiota therapy in IBD. Key Messages: The microbiota composition in IBD patients shows significant alterations compared to healthy individuals termed as “dysbiosis”. FMT and other therapeutic approaches to modify the microbiota composition have been studied in clinical trials in recent years. Efficacy has been shown in UC; however, many questions with respect to the optimization of microbiota therapy remain to be answered.

show abstract

Section: Microbiota Composition In Patients With Ibdsupporting

confidence: 63%

Microbiota Therapy in Inflammatory Bowel Disease

Biedermann,

Kreienbühl,

Rogler

2024

Visc Med

View full text Add to dashboard Cite

show abstract

“…Butyricicoccaceae have mucosal anti-inflammatory functions and are associated with short-chain fatty acid (SCFA) production [40]. Faecalibacterium are known to prevent or improve clinical symptoms related to UC by inhibiting the loss of CD4+ CD25+ Regulatory T cells (Tregs) in the spleen, thereby regulating the immune response [41]. Treg cells also play a crucial role in suppressing autoimmunity and maintaining immune tolerance [42].…”

Section: Discussionmentioning

confidence: 99%

Complementary Therapeutic Effect of Fecal Microbiota Transplantation in Ulcerative Colitis after the Response to Anti-Tumor Necrosis Factor Alpha Agent Was Lost: A Case Report

Shin,

Baek,

Cha

et al. 2024

Biomedicines

View full text Add to dashboard Cite

In patients with ulcerative colitis (UC), the development of an antidrug antibody (ADA) to anti-tumor necrosis factor (TNF)α agent is a crucial problem which aggravates the clinical course of the disease, being cited as one of the most common causes for discontinuing anti-TNFα treatment. This is due to ADA eventually causing secondary LOR, leading to discontinuation of anti-TNFα treatment. Recently, research on the microbiome and relationship between worsening UC and dysbiosis has been conducted. Further, investigations on the association between the microbiome and secondary LOR are increasing. Here, we present the therapeutic effect of fecal microbiota transplantation (FMT) on a 42-year-old man with secondary LOR and high ADA levels. FMT has recently been used for the treatment of, and for overcoming, drug resistance through microbiome modification. Stool samples were collected from the patient before and 4 weeks after FMT. Symptoms, including hematochezia and Mayo endoscopy sub-scores, improved after FMT, while ADA levels decreased by one-third to less than half the value (29 ng/mL) compared to before FMT (79 ng/mL). Additionally, the trough level of infliximab became measurable, which reflects the improvement in the area under the concentration (AUC). Butyricicoccus, Faecalibacterium, Bifidobacterium, Ligilactobacillus, Alistipes, and Odoribacter, which regulate immune responses and alleviate inflammation, also increased after FMT. We report a case in which microbiome modification by FMT increased the AUC of anti-TNFα in a patient who developed secondary LOR during anti-TNFα treatment, thereby improving symptoms and mucosal inflammation.

show abstract

“…Numerous studies have underscored the pivotal influence of gut microbiota and its metabolites on the differentiation of Treg and Th17 [103][104][105]. Certain bacteria such as Lactobacillus reuteri [106,107], Bacteroides fragilis [108][109][110], Bacteroides thetaiotaomicron [111], Clostridium [112][113][114][115], and Faecalibacterium prausnitzii [116][117][118][119] have been shown to promote Treg differentiation within the intestine. They play a crucial role in maintaining intestinal immune homeostasis and inhibiting the occurrence of inflammatory responses.…”

Section: Multiple Roles Of Gut Microbiota In Regulating Il-17-produci...mentioning

confidence: 99%

The dynamic shifts of IL-10-producing Th17 and IL-17-producing Treg in health and disease: a crosstalk between ancient "Yin-Yang" theory and modern immunology

Cui,

Wang,

et al. 2024

Cell Commun Signal

View full text Add to dashboard Cite

The changes in T regulatory cell (Treg) and T helper cell (Th) 17 ratios holds paramount importance in ensuring internal homeostasis and disease progression. Recently, novel subsets of Treg and Th17, namely IL-17-producing Treg and IL-10-producing Th17 have been identified. IL-17-producing Treg and IL-10-producing Th17 are widely considered as the intermediates during Treg/Th17 transformation. These “bi-functional” cells exhibit plasticity and have been demonstrated with important roles in multiple physiological functions and disease processes. Yin and Yang represent opposing aspects of phenomena according to the ancient Chinese philosophy “Yin-Yang” theory. Furthermore, Yin can transform into Yang, and vice versa, under specific conditions. This theory has been widely used to describe the contrasting functions of immune cells and molecules. Therefore, immune-activating populations (Th17, M1 macrophage, etc.) and immune overreaction (inflammation, autoimmunity) can be considered Yang, while immunosuppressive populations (Treg, M2 macrophage, etc.) and immunosuppression (tumor, immunodeficiency) can be considered Yin. However, another important connotation of “Yin-Yang” theory, the conversion between Yin and Yang, has been rarely documented in immune studies. The discovery of IL-17-producing Treg and IL-10-producing Th17 enriches the meaning of “Yin-Yang” theory and further promotes the relationship between ancient “Yin-Yang” theory and modern immunology. Besides, illustrating the functions of IL-17-producing Treg and IL-10-producing Th17 and mechanisms governing their differentiation provides valuable insights into the mechanisms underlying the dynamically changing statement of immune statement in health and diseases.

show abstract

Faecalibacterium prausnitzii, Bacteroides faecis and Roseburia intestinalis attenuate clinical symptoms of experimental colitis by regulating Treg/Th17 cell balance and intestinal barrier integrity

Cited by 17 publications

References 66 publications

Microbiota Therapy in Inflammatory Bowel Disease

Microbiota Therapy in Inflammatory Bowel Disease

Complementary Therapeutic Effect of Fecal Microbiota Transplantation in Ulcerative Colitis after the Response to Anti-Tumor Necrosis Factor Alpha Agent Was Lost: A Case Report

The dynamic shifts of IL-10-producing Th17 and IL-17-producing Treg in health and disease: a crosstalk between ancient "Yin-Yang" theory and modern immunology

Contact Info

Product

Resources

About